TriangleNCT02460224 · OUTCOME
Phase 1: Relative Dose Intensity (RDI) of LAG525 and PDR001
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEAN
- Unit
- percentage
- Interval / dispersion
- Standard Deviation
- Time frame
- From start of treatment until end of treatment, assessed up to 4.4 years.
What was measured
Relative dose intensity of each study drug is calculated with the following formula: 100 x actual dose intensity (mg/day)/planned dose intensity (mg/day). Japanese patients were not treated with PDR001 and therefore the RDI of this study drug is not applicable.
Analysis population: All patients in phase 1 who received at least one full or partial dose of LAG525 or PDR001.
Groups in this outcome
Phase 1: LAG525 1 mg/kg Q2W
Single-agent LAG525 1 mg/kg Q2W
Phase 1: LAG525 3 mg/kg Q2W
Single-agent LAG525 3 mg/kg Q2W
Phase 1: LAG525 5 mg/kg Q2W
Single-agent LAG525 5 mg/kg Q2W
Phase 1: LAG525 10 mg/kg Q2W
Single-agent LAG525 10 mg/kg Q2W
Phase 1: LAG525 15 mg/kg Q2W
Single-agent LAG525 15 mg/kg Q2W
Phase 1: LAG525 240 mg Q2W
Single-agent LAG525 240 mg Q2W
Phase 1: LAG525 400 mg Q2W
Single-agent LAG525 400 mg Q2W
Phase 1: LAG525 3 mg/kg Q4W
Single-agent LAG525 3 mg/kg Q4W
Phase 1: LAG525 5 mg/kg Q4W
Single-agent LAG525 5 mg/kg Q4W
Phase 1: LAG525 10 mg/kg Q4W
Single-agent LAG525 10 mg/kg Q4W
Phase 1: LAG525 400 mg Q4W
Single-agent LAG525 400 mg Q4W
Phase 1: LAG525 0.3 mg/kg Q2W + PDR001 1 mg/kg Q2W
Combination LAG525 0.3 mg/kg + PDR001 1 mg/kg (Q2W/Q2W)
Phase 1: LAG525 1 mg/kg Q2W + PDR001 1 mg/kg Q2W
Combination LAG525 1 mg/kg + PDR001 1 mg/kg (Q2W/Q2W)
Phase 1: LAG525 80 mg Q2W + PDR001 80 mg Q2W
Combination LAG525 80 mg + PDR001 80 mg (Q2W/Q2W)
Phase 1: LAG525 80 mg Q2W + PDR001 240 mg Q2W
Combination LAG525 80 mg + PDR001 240 mg (Q2W/Q2W)
Phase 1: LAG525 240 mg Q2W + PDR001 240 mg Q2W
Combination LAG525 240 mg + PDR001 240 mg (Q2W/Q2W)
Phase 1: LAG525 240 mg Q3W + PDR001 300 mg Q3W
Combination LAG525 240 mg + PDR001 300 mg (Q3W/Q3W)
Phase 1: LAG525 400 mg Q3W + PDR001 300 mg Q3W
Combination LAG525 400 mg + PDR001 300 mg (Q3W/Q3W)
Phase 1: LAG525 600 mg Q3W + PDR001 300 mg Q3W
Combination LAG525 600 mg + PDR001 300 mg (Q3W/Q3W)
Phase 1: LAG525 80 mg Q4W + PDR001 240 mg Q4W
Combination LAG525 80 mg + PDR001 240 mg (Q4W/Q4W)
Phase 1: LAG525 400 mg Q4W + PDR001 400 mg Q4W
Combination LAG525 400 mg + PDR001 400 mg (Q4W/Q4W)
Phase 1: LAG525 800 mg Q4W + PDR001 400 mg Q4W
Combination LAG525 800 mg + PDR001 400 mg (Q4W/Q4W)
Phase 1: LAG525 1000 mg Q4W + PDR001 400 mg Q4W
Combination LAG525 1000 mg + PDR001 400 mg (Q4W/Q4W)
Phase 1: LAG525 80 mg Q2W + PDR001 400 mg Q4W
Combination LAG525 80 mg + PDR001 400 mg (Q2W/Q4W)
Phase 1: LAG525 240 mg Q2W + PDR001 400 mg Q4W
Combination LAG525 240 mg + PDR001 400 mg (Q2W/Q4W)
Phase 1: LAG525 300 mg Q2W + PDR001 400 mg Q4W
Combination LAG525 300 mg + PDR001 400 mg (Q2W/Q4W)
| Group | Source count |
|---|---|
| Phase 1: LAG525 1 mg/kg Q2W | 17 |
| Phase 1: LAG525 3 mg/kg Q2W | 12 |
| Phase 1: LAG525 5 mg/kg Q2W | 6 |
| Phase 1: LAG525 10 mg/kg Q2W | 6 |
| Phase 1: LAG525 15 mg/kg Q2W | 6 |
| Phase 1: LAG525 240 mg Q2W | 30 |
| Phase 1: LAG525 400 mg Q2W | 30 |
| Phase 1: LAG525 3 mg/kg Q4W | 5 |
| Phase 1: LAG525 5 mg/kg Q4W | 6 |
| Phase 1: LAG525 10 mg/kg Q4W | 11 |
| Phase 1: LAG525 400 mg Q4W | 5 |
| Phase 1: LAG525 0.3 mg/kg Q2W + PDR001 1 mg/kg Q2W | 6 |
| Phase 1: LAG525 1 mg/kg Q2W + PDR001 1 mg/kg Q2W | 6 |
| Phase 1: LAG525 80 mg Q2W + PDR001 80 mg Q2W | 6 |
| Phase 1: LAG525 80 mg Q2W + PDR001 240 mg Q2W | 5 |
| Phase 1: LAG525 240 mg Q2W + PDR001 240 mg Q2W | 6 |
| Phase 1: LAG525 240 mg Q3W + PDR001 300 mg Q3W | 20 |
| Phase 1: LAG525 400 mg Q3W + PDR001 300 mg Q3W | 6 |
| Phase 1: LAG525 600 mg Q3W + PDR001 300 mg Q3W | 12 |
| Phase 1: LAG525 80 mg Q4W + PDR001 240 mg Q4W | 7 |
| Phase 1: LAG525 400 mg Q4W + PDR001 400 mg Q4W | 6 |
| Phase 1: LAG525 800 mg Q4W + PDR001 400 mg Q4W | 12 |
| Phase 1: LAG525 1000 mg Q4W + PDR001 400 mg Q4W | 6 |
| Phase 1: LAG525 80 mg Q2W + PDR001 400 mg Q4W | 11 |
| Phase 1: LAG525 240 mg Q2W + PDR001 400 mg Q4W | 6 |
| Phase 1: LAG525 300 mg Q2W + PDR001 400 mg Q4W | 6 |
Reported measurements
LAG525, ROW patients
| Group | Source count |
|---|---|
| Phase 1: LAG525 1 mg/kg Q2W | 13 |
| Phase 1: LAG525 3 mg/kg Q2W | 12 |
| Phase 1: LAG525 5 mg/kg Q2W | 6 |
| Phase 1: LAG525 10 mg/kg Q2W | 6 |
| Phase 1: LAG525 15 mg/kg Q2W | 6 |
| Phase 1: LAG525 240 mg Q2W | 25 |
| Phase 1: LAG525 400 mg Q2W | 24 |
| Phase 1: LAG525 3 mg/kg Q4W | 5 |
| Phase 1: LAG525 5 mg/kg Q4W | 6 |
| Phase 1: LAG525 10 mg/kg Q4W | 11 |
| Phase 1: LAG525 400 mg Q4W | 5 |
| Phase 1: LAG525 0.3 mg/kg Q2W + PDR001 1 mg/kg Q2W | 6 |
| Phase 1: LAG525 1 mg/kg Q2W + PDR001 1 mg/kg Q2W | 6 |
| Phase 1: LAG525 80 mg Q2W + PDR001 80 mg Q2W | 6 |
| Phase 1: LAG525 80 mg Q2W + PDR001 240 mg Q2W | 5 |
| Phase 1: LAG525 240 mg Q2W + PDR001 240 mg Q2W | 6 |
| Phase 1: LAG525 240 mg Q3W + PDR001 300 mg Q3W | 20 |
| Phase 1: LAG525 400 mg Q3W + PDR001 300 mg Q3W | 6 |
| Phase 1: LAG525 600 mg Q3W + PDR001 300 mg Q3W | 12 |
| Phase 1: LAG525 80 mg Q4W + PDR001 240 mg Q4W | 7 |
| Phase 1: LAG525 400 mg Q4W + PDR001 400 mg Q4W | 6 |
| Phase 1: LAG525 800 mg Q4W + PDR001 400 mg Q4W | 12 |
| Phase 1: LAG525 1000 mg Q4W + PDR001 400 mg Q4W | 6 |
| Phase 1: LAG525 80 mg Q2W + PDR001 400 mg Q4W | 11 |
| Phase 1: LAG525 240 mg Q2W + PDR001 400 mg Q4W | 6 |
| Phase 1: LAG525 300 mg Q2W + PDR001 400 mg Q4W | 6 |
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Phase 1: LAG525 1 mg/kg Q2W | 98.9 | 3.93 | Not reported | Not reported | Not reported |
| Phase 1: LAG525 3 mg/kg Q2W | 100 | 0 | Not reported | Not reported | Not reported |
| Phase 1: LAG525 5 mg/kg Q2W | 94.4 | 13.61 | Not reported | Not reported | Not reported |
| Phase 1: LAG525 10 mg/kg Q2W | 100 | 0 | Not reported | Not reported | Not reported |
| Phase 1: LAG525 15 mg/kg Q2W | 98.2 | 4.47 | Not reported | Not reported | Not reported |
| Phase 1: LAG525 240 mg Q2W | 99.0 | 5.00 | Not reported | Not reported | Not reported |
| Phase 1: LAG525 400 mg Q2W | 99.9 | 0.60 | Not reported | Not reported | Not reported |
| Phase 1: LAG525 3 mg/kg Q4W | 100 | 0 | Not reported | Not reported | Not reported |
| Phase 1: LAG525 5 mg/kg Q4W | 100 | 0 | Not reported | Not reported | Not reported |
| Phase 1: LAG525 10 mg/kg Q4W | 100 | 0 | Not reported | Not reported | Not reported |
| Phase 1: LAG525 400 mg Q4W | 100 | 0 | Not reported | Not reported | Not reported |
| Phase 1: LAG525 0.3 mg/kg Q2W + PDR001 1 mg/kg Q2W | 97.4 | 6.27 | Not reported | Not reported | Not reported |
| Phase 1: LAG525 1 mg/kg Q2W + PDR001 1 mg/kg Q2W | 100 | 0 | Not reported | Not reported | Not reported |
| Phase 1: LAG525 80 mg Q2W + PDR001 80 mg Q2W | 99.7 | 0.84 | Not reported | Not reported | Not reported |
| Phase 1: LAG525 80 mg Q2W + PDR001 240 mg Q2W | 100 | 0 | Not reported | Not reported | Not reported |
| Phase 1: LAG525 240 mg Q2W + PDR001 240 mg Q2W | 99.6 | 0.93 | Not reported | Not reported | Not reported |
| Phase 1: LAG525 240 mg Q3W + PDR001 300 mg Q3W | 97.8 | 5.27 | Not reported | Not reported | Not reported |
| Phase 1: LAG525 400 mg Q3W + PDR001 300 mg Q3W | 100 | 0 | Not reported | Not reported | Not reported |
| Phase 1: LAG525 600 mg Q3W + PDR001 300 mg Q3W | 100 | 0 | Not reported | Not reported | Not reported |
| Phase 1: LAG525 80 mg Q4W + PDR001 240 mg Q4W | 100 | 0 | Not reported | Not reported | Not reported |
| Phase 1: LAG525 400 mg Q4W + PDR001 400 mg Q4W | 100 | 0 | Not reported | Not reported | Not reported |
| Phase 1: LAG525 800 mg Q4W + PDR001 400 mg Q4W | 100 | 0 | Not reported | Not reported | Not reported |
| Phase 1: LAG525 1000 mg Q4W + PDR001 400 mg Q4W | 100 | 0 | Not reported | Not reported | Not reported |
| Phase 1: LAG525 80 mg Q2W + PDR001 400 mg Q4W | 97.7 | 7.54 | Not reported | Not reported | Not reported |
| Phase 1: LAG525 240 mg Q2W + PDR001 400 mg Q4W | 100 | 0 | Not reported | Not reported | Not reported |
| Phase 1: LAG525 300 mg Q2W + PDR001 400 mg Q4W | 100 | 0 | Not reported | Not reported | Not reported |
PDR001, ROW patients
| Group | Source count |
|---|---|
| Phase 1: LAG525 1 mg/kg Q2W | 0 |
| Phase 1: LAG525 3 mg/kg Q2W | 0 |
| Phase 1: LAG525 5 mg/kg Q2W | 0 |
| Phase 1: LAG525 10 mg/kg Q2W | 0 |
| Phase 1: LAG525 15 mg/kg Q2W | 0 |
| Phase 1: LAG525 240 mg Q2W | 0 |
| Phase 1: LAG525 400 mg Q2W | 0 |
| Phase 1: LAG525 3 mg/kg Q4W | 0 |
| Phase 1: LAG525 5 mg/kg Q4W | 0 |
| Phase 1: LAG525 10 mg/kg Q4W | 0 |
| Phase 1: LAG525 400 mg Q4W | 0 |
| Phase 1: LAG525 0.3 mg/kg Q2W + PDR001 1 mg/kg Q2W | 6 |
| Phase 1: LAG525 1 mg/kg Q2W + PDR001 1 mg/kg Q2W | 6 |
| Phase 1: LAG525 80 mg Q2W + PDR001 80 mg Q2W | 6 |
| Phase 1: LAG525 80 mg Q2W + PDR001 240 mg Q2W | 5 |
| Phase 1: LAG525 240 mg Q2W + PDR001 240 mg Q2W | 6 |
| Phase 1: LAG525 240 mg Q3W + PDR001 300 mg Q3W | 20 |
| Phase 1: LAG525 400 mg Q3W + PDR001 300 mg Q3W | 6 |
| Phase 1: LAG525 600 mg Q3W + PDR001 300 mg Q3W | 12 |
| Phase 1: LAG525 80 mg Q4W + PDR001 240 mg Q4W | 7 |
| Phase 1: LAG525 400 mg Q4W + PDR001 400 mg Q4W | 6 |
| Phase 1: LAG525 800 mg Q4W + PDR001 400 mg Q4W | 12 |
| Phase 1: LAG525 1000 mg Q4W + PDR001 400 mg Q4W | 6 |
| Phase 1: LAG525 80 mg Q2W + PDR001 400 mg Q4W | 11 |
| Phase 1: LAG525 240 mg Q2W + PDR001 400 mg Q4W | 6 |
| Phase 1: LAG525 300 mg Q2W + PDR001 400 mg Q4W | 6 |
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Phase 1: LAG525 0.3 mg/kg Q2W + PDR001 1 mg/kg Q2W | 97.3 | 6.72 | Not reported | Not reported | Not reported |
| Phase 1: LAG525 1 mg/kg Q2W + PDR001 1 mg/kg Q2W | 100 | 0 | Not reported | Not reported | Not reported |
| Phase 1: LAG525 80 mg Q2W + PDR001 80 mg Q2W | 97.6 | 5.00 | Not reported | Not reported | Not reported |
| Phase 1: LAG525 80 mg Q2W + PDR001 240 mg Q2W | 100 | 0 | Not reported | Not reported | Not reported |
| Phase 1: LAG525 240 mg Q2W + PDR001 240 mg Q2W | 100 | 0 | Not reported | Not reported | Not reported |
| Phase 1: LAG525 240 mg Q3W + PDR001 300 mg Q3W | 98.0 | 4.95 | Not reported | Not reported | Not reported |
| Phase 1: LAG525 400 mg Q3W + PDR001 300 mg Q3W | 100 | 0 | Not reported | Not reported | Not reported |
| Phase 1: LAG525 600 mg Q3W + PDR001 300 mg Q3W | 100 | 0 | Not reported | Not reported | Not reported |
| Phase 1: LAG525 80 mg Q4W + PDR001 240 mg Q4W | 100 | 0 | Not reported | Not reported | Not reported |
| Phase 1: LAG525 400 mg Q4W + PDR001 400 mg Q4W | 100 | 0 | Not reported | Not reported | Not reported |
| Phase 1: LAG525 800 mg Q4W + PDR001 400 mg Q4W | 100 | 0 | Not reported | Not reported | Not reported |
| Phase 1: LAG525 1000 mg Q4W + PDR001 400 mg Q4W | 100 | 0 | Not reported | Not reported | Not reported |
| Phase 1: LAG525 80 mg Q2W + PDR001 400 mg Q4W | 100 | 0 | Not reported | Not reported | Not reported |
| Phase 1: LAG525 240 mg Q2W + PDR001 400 mg Q4W | 100 | 0 | Not reported | Not reported | Not reported |
| Phase 1: LAG525 300 mg Q2W + PDR001 400 mg Q4W | 100 | 0 | Not reported | Not reported | Not reported |
LAG525, Japanese patients
| Group | Source count |
|---|---|
| Phase 1: LAG525 1 mg/kg Q2W | 4 |
| Phase 1: LAG525 3 mg/kg Q2W | 0 |
| Phase 1: LAG525 5 mg/kg Q2W | 0 |
| Phase 1: LAG525 10 mg/kg Q2W | 0 |
| Phase 1: LAG525 15 mg/kg Q2W | 0 |
| Phase 1: LAG525 240 mg Q2W | 5 |
| Phase 1: LAG525 400 mg Q2W | 6 |
| Phase 1: LAG525 3 mg/kg Q4W | 0 |
| Phase 1: LAG525 5 mg/kg Q4W | 0 |
| Phase 1: LAG525 10 mg/kg Q4W | 0 |
| Phase 1: LAG525 400 mg Q4W | 0 |
| Phase 1: LAG525 0.3 mg/kg Q2W + PDR001 1 mg/kg Q2W | 0 |
| Phase 1: LAG525 1 mg/kg Q2W + PDR001 1 mg/kg Q2W | 0 |
| Phase 1: LAG525 80 mg Q2W + PDR001 80 mg Q2W | 0 |
| Phase 1: LAG525 80 mg Q2W + PDR001 240 mg Q2W | 0 |
| Phase 1: LAG525 240 mg Q2W + PDR001 240 mg Q2W | 0 |
| Phase 1: LAG525 240 mg Q3W + PDR001 300 mg Q3W | 0 |
| Phase 1: LAG525 400 mg Q3W + PDR001 300 mg Q3W | 0 |
| Phase 1: LAG525 600 mg Q3W + PDR001 300 mg Q3W | 0 |
| Phase 1: LAG525 80 mg Q4W + PDR001 240 mg Q4W | 0 |
| Phase 1: LAG525 400 mg Q4W + PDR001 400 mg Q4W | 0 |
| Phase 1: LAG525 800 mg Q4W + PDR001 400 mg Q4W | 0 |
| Phase 1: LAG525 1000 mg Q4W + PDR001 400 mg Q4W | 0 |
| Phase 1: LAG525 80 mg Q2W + PDR001 400 mg Q4W | 0 |
| Phase 1: LAG525 240 mg Q2W + PDR001 400 mg Q4W | 0 |
| Phase 1: LAG525 300 mg Q2W + PDR001 400 mg Q4W | 0 |
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Phase 1: LAG525 1 mg/kg Q2W | 100 | 0 | Not reported | Not reported | Not reported |
| Phase 1: LAG525 240 mg Q2W | 98.0 | 4.47 | Not reported | Not reported | Not reported |
| Phase 1: LAG525 400 mg Q2W | 100 | 0 | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- spread
- 3.93
- value
- 98.9
- group Id
- OG001
- spread
- 0
- value
- 100
- group Id
- OG002
- spread
- 13.61
- value
- 94.4
- group Id
- OG003
- spread
- 0
- value
- 100
- group Id
- OG004
- spread
- 4.47
- value
- 98.2
- group Id
- OG005
- spread
- 5.00
- value
- 99.0
- group Id
- OG006
- spread
- 0.60
- value
- 99.9
- group Id
- OG007
- spread
- 0
- value
- 100
- group Id
- OG008
- spread
- 0
- value
- 100
- group Id
- OG009
- spread
- 0
- value
- 100
- group Id
- OG010
- spread
- 0
- value
- 100
- group Id
- OG011
- spread
- 6.27
- value
- 97.4
- denoms
- counts
- group Id
- OG000
- value
- 13
- group Id
- OG001
- value
- 12
- group Id
- OG002
- value
- 6
- group Id
- OG003
- value
- 6
- group Id
- OG004
- value
- 6
- group Id
- OG005
- value
- 25
- group Id
- OG006
- value
- 24
- group Id
- OG007
- value
- 5
- group Id
- OG008
- value
- 6
- group Id
- OG009
- value
- 11
- group Id
- OG010
- value
- 5
- group Id
- OG011
- value
- 6
- units
- Participants
- title
- LAG525, ROW patients
- categories
- measurements
- group Id
- OG011
- spread
- 6.72
- value
- 97.3
- group Id
- OG012
- spread
- 0
- value
- 100
- group Id
- OG013
- spread
- 5.00
- value
- 97.6
- group Id
- OG014
- spread
- 0
- value
- 100
- group Id
- OG015
- spread
- 0
- value
- 100
- group Id
- OG016
- spread
- 4.95
- value
- 98.0
- group Id
- OG017
- spread
- 0
- value
- 100
- group Id
- OG018
- spread
- 0
- value
- 100
- group Id
- OG019
- spread
- 0
- value
- 100
- group Id
- OG020
- spread
- 0
- value
- 100
- group Id
- OG021
- spread
- 0
- value
- 100
- group Id
- OG022
- spread
- 0
- value
- 100
- denoms
- counts
- group Id
- OG000
- value
- 0
- group Id
- OG001
- value
- 0
- group Id
- OG002
- value
- 0
- group Id
- OG003
- value
- 0
- group Id
- OG004
- value
- 0
- group Id
- OG005
- value
- 0
- group Id
- OG006
- value
- 0
- group Id
- OG007
- value
- 0
- group Id
- OG008
- value
- 0
- group Id
- OG009
- value
- 0
- group Id
- OG010
- value
- 0
- group Id
- OG011
- value
- 6
- units
- Participants
- title
- PDR001, ROW patients
- categories
- measurements
- group Id
- OG000
- spread
- 0
- value
- 100
- group Id
- OG005
- spread
- 4.47
- value
- 98.0
- group Id
- OG006
- spread
- 0
- value
- 100
- denoms
- counts
- group Id
- OG000
- value
- 4
- group Id
- OG001
- value
- 0
- group Id
- OG002
- value
- 0
- group Id
- OG003
- value
- 0
- group Id
- OG004
- value
- 0
- group Id
- OG005
- value
- 5
- group Id
- OG006
- value
- 6
- group Id
- OG007
- value
- 0
- group Id
- OG008
- value
- 0
- group Id
- OG009
- value
- 0
- group Id
- OG010
- value
- 0
- group Id
- OG011
- value
- 0
- units
- Participants
- title
- LAG525, Japanese patients
- denoms
- counts
- group Id
- OG000
- value
- 17
- group Id
- OG001
- value
- 12
- group Id
- OG002
- value
- 6
- group Id
- OG003
- value
- 6
- group Id
- OG004
- value
- 6
- group Id
- OG005
- value
- 30
- group Id
- OG006
- value
- 30
- group Id
- OG007
- value
- 5
- group Id
- OG008
- value
- 6
- group Id
- OG009
- value
- 11
- group Id
- OG010
- value
- 5
- group Id
- OG011
- value
- 6
- units
- Participants
- description
- Relative dose intensity of each study drug is calculated with the following formula: 100 x actual dose intensity (mg/day)/planned dose intensity (mg/day). Japanese patients were not treated with PDR001 and therefore the RDI of this study drug is not applicable.
- dispersion Type
- Standard Deviation
- groups
- description
- Single-agent LAG525 1 mg/kg Q2W
- id
- OG000
- title
- Phase 1: LAG525 1 mg/kg Q2W
- description
- Single-agent LAG525 3 mg/kg Q2W
- id
- OG001
- title
- Phase 1: LAG525 3 mg/kg Q2W
- description
- Single-agent LAG525 5 mg/kg Q2W
- id
- OG002
- title
- Phase 1: LAG525 5 mg/kg Q2W
- description
- Single-agent LAG525 10 mg/kg Q2W
- id
- OG003
- title
- Phase 1: LAG525 10 mg/kg Q2W
- description
- Single-agent LAG525 15 mg/kg Q2W
- id
- OG004
- title
- Phase 1: LAG525 15 mg/kg Q2W
- description
- Single-agent LAG525 240 mg Q2W
- id
- OG005
- title
- Phase 1: LAG525 240 mg Q2W
- description
- Single-agent LAG525 400 mg Q2W
- id
- OG006
- title
- Phase 1: LAG525 400 mg Q2W
- description
- Single-agent LAG525 3 mg/kg Q4W
- id
- OG007
- title
- Phase 1: LAG525 3 mg/kg Q4W
- description
- Single-agent LAG525 5 mg/kg Q4W
- id
- OG008
- title
- Phase 1: LAG525 5 mg/kg Q4W
- description
- Single-agent LAG525 10 mg/kg Q4W
- id
- OG009
- title
- Phase 1: LAG525 10 mg/kg Q4W
- description
- Single-agent LAG525 400 mg Q4W
- id
- OG010
- title
- Phase 1: LAG525 400 mg Q4W
- description
- Combination LAG525 0.3 mg/kg + PDR001 1 mg/kg (Q2W/Q2W)
- id
- OG011
- title
- Phase 1: LAG525 0.3 mg/kg Q2W + PDR001 1 mg/kg Q2W
- param Type
- MEAN
- population Description
- All patients in phase 1 who received at least one full or partial dose of LAG525 or PDR001.
- reporting Status
- POSTED
- time Frame
- From start of treatment until end of treatment, assessed up to 4.4 years.
- title
- Phase 1: Relative Dose Intensity (RDI) of LAG525 and PDR001
- type
- SECONDARY
- unit Of Measure
- percentage
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice